BioCopy
Last verified 2026-05-06. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $9.9Mattributed |
|---|---|
| Latest round | series-a, $9.9M, 2025-09-01attributed |
| Founded | 2018 |
| Headquarters | Basel |
| Industry | bio |
| Stage | series-a |
| Website | biocopy.com |
ValidaTe platform combines AI, large-scale peptide screening and a fully automated lab to design multi-specific antibodies against pHLA cancer targets. Sells to oncology biotechs and pharma teams discovering complex biologics. Screens up to 25,000 candidates in parallel and claims to shrink three-year discovery cycles to about 12 months.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-01 | series-a | $9.9M | undisclosed |
Detected tech stack
Vercel, Next.js, React, Webpack
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $9.9M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $9.9M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | biocopy.com, read 2026-05-06 |
| Description | self-reported | biocopy.com, read 2026-05-06 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.